Clearpoint Neuro Inc (CLPT)vsDexCom Inc (DXCM)
CLPT
Clearpoint Neuro Inc
$13.46
-1.90%
HEALTHCARE · Cap: $418.52M
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 11653% more annual revenue ($4.97B vs $42.28M). DXCM leads profitability with a 20.1% profit margin vs -81.8%. CLPT appears more attractively valued with a PEG of 0.61. DXCM earns a higher WallStSmart Score of 74/100 (B).
CLPT
Avoid33
out of 100
Grade: F
DXCM
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.7%
Fair Value
$15.14
Current Price
$13.46
$1.68 discount
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
18.1% revenue growth
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 38.5x book value
ROE of -320.8% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CLPT
The strongest argument for CLPT centers on PEG Ratio, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : CLPT
The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.93 is elevated, increasing financial risk.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
CLPT profiles as a growth stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
CLPT is growing revenue faster at 18.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 33/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?